* ASX-listed shares of AVITA Medical AVH.AX RCEL.O fall as much as 20.2% to A$3.470
** Stock last down about 18.8%, set for deepest one-day decline since Oct 2023
** Regenerative medicine firm cuts forecast for the fourth time in five quarters
** Says it expects Q4 commercial revenue of about $18.4 mln, compared to its prior guidance range of $22.3 mln to $24.3 mln
** Stock hits lowest price level since mid-Nov
** About 2 mln shares change hands, highest since mid-Aug 2022
** Stock fell 0.9% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。